AtheroNova Competitors

Acusphere (OTCMKTS:ACUS) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Volatility & Risk

Acusphere has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Acusphere and AtheroNova, as provided by MarketBeat.

Earnings and Valuation

This table compares Acusphere and AtheroNova's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Acusphere and AtheroNova's net margins, return on equity and return on assets.

Summary

Acusphere beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Volatility and Risk

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Affymax and AtheroNova, as reported by MarketBeat.com.

Earnings & Valuation

This table compares Affymax and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Affymax and AtheroNova's net margins, return on equity and return on assets.

Summary

Affymax beats AtheroNova on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ARYx Therapeutics and AtheroNova, as reported by MarketBeat.com.

Earnings & Valuation

This table compares ARYx Therapeutics and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ARYx Therapeutics and AtheroNova's net margins, return on equity and return on assets.

Summary

ARYx Therapeutics beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for China Botanic Pharmaceutical and AtheroNova, as reported by MarketBeat.com.

Profitability

This table compares China Botanic Pharmaceutical and AtheroNova's net margins, return on equity and return on assets.

Volatility and Risk

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats AtheroNova on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Volatility & Risk

AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares AtheroNova and China Dongsheng International's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares AtheroNova and China Dongsheng International's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for AtheroNova and China Dongsheng International, as reported by MarketBeat.com.

Summary

China Dongsheng International beats AtheroNova on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and China Health Industries (OTCMKTS:CHHE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Volatility & Risk

AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and China Health Industries' gross revenue, earnings per share and valuation.

China Health Industries has higher revenue and earnings than AtheroNova.

Profitability

This table compares AtheroNova and China Health Industries' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AtheroNova and China Health Industries, as reported by MarketBeat.com.

Summary

China Health Industries beats AtheroNova on 5 of the 5 factors compared between the two stocks.